Brokers Issue Forecasts for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Intellia Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.38) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2027 earnings at ($0.75) EPS and FY2027 earnings at ($3.11) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter last year, the firm posted ($1.10) earnings per share.

Several other brokerages have also recently issued reports on NTLA. Sanford C. Bernstein increased their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research note on Wednesday. Morgan Stanley boosted their price objective on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada increased their price objective on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $20.25.

Intellia Therapeutics Stock Up 2.1%

Shares of NTLA stock opened at $14.28 on Thursday. The firm has a 50 day moving average of $13.65 and a two-hundred day moving average of $12.07. The stock has a market capitalization of $2.00 billion, a PE ratio of -4.03 and a beta of 1.93. Intellia Therapeutics has a 52 week low of $6.83 and a 52 week high of $28.25.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NTLA. Contrarius Group Holdings Ltd lifted its holdings in shares of Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after purchasing an additional 4,337,428 shares during the period. ARK Investment Management LLC raised its position in Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after buying an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp lifted its stake in shares of Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after acquiring an additional 1,447,967 shares during the period. Finally, Jupiter Asset Management Ltd. purchased a new stake in shares of Intellia Therapeutics in the third quarter valued at about $23,519,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Intellia Therapeutics and kept a $25 price target, implying meaningful upside from current levels. The firm also published 2027 estimates that suggest losses should narrow over time as the company advances its gene-editing programs. Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright
• Positive Sentiment: Recent company discussion has focused on progress in late-stage gene-editing assets, including plans for a 2027 launch for lonvo-z after strong phase III hereditary angioedema data, which may be helping support investor sentiment. NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
• Neutral Sentiment: Wedbush maintained a Neutral/Hold-type stance on NTLA, with one note keeping a $12 price target and another reaffirming a neutral view. This adds a cautious offset to the more bullish HC Wainwright call. Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
• Negative Sentiment: Brookline Capital Markets trimmed several near-term earnings estimates for Intellia, reflecting continued expected losses and some caution on the company’s expense and development profile. Intellia Therapeutics stock information

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.